Thyroid cancer is the most commonly diagnosed endocrine malignancy. In collaboration with Professor Chris Gilfillan at Box Hill Hospital, Dr. Michael Mond is exploring the molecular changes that lead to thyroid cancer.
In parallel with the Endocrinology Unit’s increased focus on the management of thyroid cancer through the development of protocols for treatment, multidisciplinary meetings, and a multidisciplinary clinic, we have initiated a program of research into the molecular pathogenesis of thyroid cancer.
Focused on mutational analysis of thyroid cancers and thyroid cancer biopsies, current research will improve understanding of the role of nuclear receptors in thyroid cancer and on transcription factors in thyroid cancer.
Professor Chris Gilfillan, Eastern Health
Associate Professor Rory Clifton-Bligh, Royal North Shore Hospital
Mond, M., Alexiadis, M., Eriksson, N., Davis, M., Muscat, G., Fuller, P.J. and Gilfillan, C.
Nuclear receptor expression in human differentiated thyroid tumors. Thyroid 24: 1000-1011, 2014.
Mond, M., Alexiadis, M., Fuller, P.J. and Gilfillan, C. Mutation profile of differentiated thyroid tumours in an urban Australian population. Internal Medicine Journal 44: 727-734, 2014.